Patient Driven Research – the KCCure Chromophobe Research Grant

“Has anyone done any fundraising or advocacy projects to help raise money or awareness for Chromophobe RCC? Every specialist I talk to mentions the limited research in chromophobe since we are not as common as clear cell.” – Catherine Yutmeyer, chromophobe kidney cancer patient At KCCure, we pride ourselves on being an evidence-based, patient-driven advocacy organization. But when I saw this post in our chromophobe patient community, I realized that we were relying too heavily on providers to set the priorities for our research grant program. To be true to our values, we needed to bring patients into the process. Rare Subtypes Our communities for rare subtypes of kidney cancer have grown dramatically over the past few years. Over and over again, we hear the desperation of people rais...

In Remembrance 2020

This year, more than 150,000 people died worldwide from kidney cancer. This video represents just a fraction of the toll that this disease has taken. Please take a moment to honor and remember those that we lost this year.

Fear of Cancer Recurrence – and why it matters so much

Seventy-five percent of patients will be diagnosed with localized disease – cancer that is confined to the kidney. For most of these patients, surgery will be curative. Because of that fact, few resources exist to support these patients. The assumption is that they are “cured” and no longer need additional care. They are “lucky.” The problem with this logic is that 20 to 40 percent of those patients will eventually face a recurrence in their lifetime. Patients live in fear, wondering if they will be one of those people. While algorithms have been created, there still isn’t any consensus on how to risk stratify patients with localized disease. There is also no consensus on the type or frequency of follow-up care they should receive. Many patients are unaw...

KCCure All-Star – Dr. Ulka Vaishampayan

Finding a kidney cancer specialist can be daunting. KCCure Patient Communities offer excellent opportunities to get recommendations from others. Learn more at KCCure.

Biopsy for Kidney Cancer – Communicating Changes in Practice

One question that is routinely posted in our kidney cancer patient communities is: should I have a biopsy of my kidney tumor? The resounding chorus from others is almost always an emphatic: “NO! “it’s too dangerous” “you’ll spread the cancer.” For more than two decades, the use of biopsy in managing renal cell carcinoma has been shifting dramatically. Advances in cytological techniques as well as increases in the number of unnecessary surgeries have expanded the role of renal mass biopsy. The myth that renal mass biopsy is dangerous has also largely been dispelled by multiple studies.[1] Despite the fact that biopsy rates are increasing, that the procedure is known to be safe, and that it can result in a reduction in unnecessary surgeries, the shared view in patient communities remains res...

Putting the Tie Back in July!

Every July, we hold our month long, “No Tie July” fundraising effort to raise money for kidney cancer. But this year is different. This year many of us wish we could wear a tie. Offices and workplaces around the world remain closed. And even once workplaces reopen, many people won’t have jobs to go back to. We know that everyone is struggling in this uncertain environment. If you can make a donation, we are sincerely grateful and all funds will go to fund our research grant program. But if you can’t, there are great ways to participate and make a meaningful difference for patients. This July, instead of taking off our ties, we’re celebrating TIES – the ties that bind us and bring us closer together. What can you do? Put your tie back on! Share a photo wearing a tie or dressed up for w...

Treatment Advances in RCC

April 20, 2020 Today, Exelixis and BMS announced positive results from a Phase 3 trial combining Cabometyx (cabozantinib) with Opdivo (nivolumab) as a first-line treatment in advanced RCC. What does that mean for patients? In trial, the combination of Opdivo+Cabometyx showed superiority in both tumor control and overall survival versus patients who were treated with Sutent (sunitinib) alone. More information about the results of this trial will be reported out soon and the companies will likely file for approval from the U.S. Food and Drug Administration (FDA) in the next few months. When will it be available? We cannot say for certain when this new drug combination will be approved and available for patients. However, based on previous experience, our prediction is that it will likely hap...

March is Kidney Cancer Awareness Month

Help us tell the world that kidney cancer exists, that we’re fighting and that we need a cure! During Kidney Cancer Awareness Month: Visit us at KCCure each day, where we’ll share a new story from someone whose life has been touched by kidney cancer. We share Kidney Cancer Patient Stories to let others know that they’re not alone. SHOW YOUR COLORS! Every Friday, wear orange or green to raise awareness for #kidneycancer. Share your photos on Facebook, Twitter and Instagram! Choose a KCCure overlay for your Facebook profile and let others know why kidney cancer research is important to you! For some cancers, “awareness” campaigns save lives.  Signs and symptoms or early diagnostic tests can mean catching a cancer earlier – in a more treatable form.  But in kidney cancer, signs and symptoms u...

KCCure Awards $200,000 in new Kidney Cancer Research Funding

WASHINGTON – The Kidney Cancer Research Alliance (KCCure) announced awards totalling $200,000 in new funding to researchers at four institutions working on ground-breaking research in kidney cancer. The recipients are: Rosa Nadal Rios, MD, Ph.D., Cellular and Molecular Therapeutics Branch at the National Institutes of Health for her research in the Role of epigenetic reprogramming on Human Endogenous Retroviruses type E (HERV-E) expression and impact on HERV-E directed immunotherapy in renal cell carcinoma (RCC). ($100,000 award) Haifeng Yang, Ph.D. Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University for his research Investigating the anti-tumor effect of a STING agonist on BAP1-deficient ccRCC tumors. ($50,000 award) Pavlos Msaouel, MD, PhD, PhD Depa...

Celebrating Kidney Cancer Caregivers – Zach Juno

Zach Juno shares his journey as a caregiver and fierce advocate for his mother, a stage 4 kidney cancer survivor. I’ll never forget hearing it. “Your mother has a tumor the size of a tennis ball on her left kidney” That was the day I became my Mother’s advocate and cancer caregiver. This was in March of 2006 and the landscape of kidney cancer was so different.  We kept reading things like “Renal Cell Carcinoma doesn’t respond to chemotherapy.” I immediately started reading statistics on the disease and remember breaking down in my living room. My mother, who has always been the center of my world and only 58 years old at the time had cancer and I just wanted to save her. I think I was trying to save myself too.  We were referred to a Urologist in the town she lives in. Our whole fami...

  • 1
  • 2
  • 8

Lost Password


Subscribe for updates!